基于结构的ASK1抑制剂设计：作为心力衰竭潜在治疗药物
Structure-Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure.
作者信息
Lanier Marion, Pickens Jason, Bigi Simone V, Bradshaw-Pierce Erica L, Chambers Alison, Cheruvallath Zacharia S, Cole Derek, Dougan Douglas R, Ermolieff Jacques, Gibson Tony, Halkowycz Petro, Hirokawa Aki, Ivetac Anthony, Miura Joanne, Nunez Evan, Sabat Mark, Tyhonas John, Wang Haixia, Wang Xiaolun, Swann Steve
机构信息
Departments of Medicinal Chemistry, Drug Metabolism Pharmacokinetics, Structural Biology, and Discovery Biology, Gastrointestinal Drug Discovery Unit, Takeda Pharmaceuticals , 10410 Science Center Drive, San Diego, California 92121, United States.
出版信息
ACS Med Chem Lett. 2017 Feb 8;8(3):316-320. doi: 10.1021/acsmedchemlett.6b00481. eCollection 2017 Mar 9.
Abstract
Apoptosis signal-regulating kinase 1 (ASK1/MAP3K) is a mitogen-activated protein kinase family member shown to contribute to acute ischemia/reperfusion injury. Using structure-based drug design, deconstruction, and reoptimization of a known ASK1 inhibitor, a lead compound was identified. This compound displayed robust MAP3K pathway inhibition and reduction of infarct size in an isolated perfused heart model of cardiac injury.
摘要
凋亡信号调节激酶1（ASK1/MAP3K）是一种丝裂原活化蛋白激酶家族成员，已被证明与急性缺血/再灌注损伤有关。通过基于结构的药物设计、解构和对已知ASK1抑制剂的重新优化，确定了一种先导化合物。在离体灌注心脏损伤模型中，该化合物表现出强大的MAP3K途径抑制作用并减小了梗死面积。
相似文献
1
Structure-Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure.基于结构的ASK1抑制剂设计：作为心力衰竭潜在治疗药物
ACS Med Chem Lett. 2017 Feb 8;8(3):316-320. doi: 10.1021/acsmedchemlett.6b00481. eCollection 2017 Mar 9.
2
Structure-guided optimization of a novel class of ASK1 inhibitors with increased sp character and an exquisite selectivity profile.基于结构的新型 ASK1 抑制剂的优化：增加 sp 特征和精细的选择性特征。
Bioorg Med Chem Lett. 2020 Sep 1;30(17):127405. doi: 10.1016/j.bmcl.2020.127405. Epub 2020 Jul 12.
3
Structure-based drug design of novel ASK1 inhibitors using an integrated lead optimization strategy.使用综合先导优化策略进行新型ASK1抑制剂的基于结构的药物设计。
Bioorg Med Chem Lett. 2017 Apr 15;27(8):1709-1713. doi: 10.1016/j.bmcl.2017.02.079. Epub 2017 Mar 2.
4
Therapeutic application of apoptosis signal-regulating kinase 1 inhibitors.凋亡信号调节激酶1抑制剂的治疗应用
Adv Biol Regul. 2017 Dec;66:85-90. doi: 10.1016/j.jbior.2017.10.004. Epub 2017 Oct 16.
5
An apoptosis signal-regulating kinase 1 inhibitor reduces cardiomyocyte apoptosis and infarct size in a rat ischemia-reperfusion model.凋亡信号调节激酶 1 抑制剂可减少大鼠缺血再灌注模型中心肌细胞凋亡和梗死面积。
J Cardiovasc Pharmacol. 2012 Sep;60(3):276-82. doi: 10.1097/FJC.0b013e31825ea0fa.
6
Involvement of mitogen activated kinase kinase 7 intracellular signalling pathway in Sunitinib-induced cardiotoxicity.丝裂原活化蛋白激酶激酶 7 细胞内信号通路在舒尼替尼诱导的心脏毒性中的作用。
Toxicology. 2018 Feb 1;394:72-83. doi: 10.1016/j.tox.2017.12.005. Epub 2017 Dec 14.
7
Apoptosis signal-regulating kinase 1 is involved not only in apoptosis but also in non-apoptotic cardiomyocyte death.凋亡信号调节激酶1不仅参与细胞凋亡，还参与非凋亡性心肌细胞死亡。
Biochem Biophys Res Commun. 2005 Jul 29;333(2):562-7. doi: 10.1016/j.bbrc.2005.05.151.
8
ASK1 and its role in cardiovascular and other disorders: available treatments and future prospects.ASK1 及其在心血管和其他疾病中的作用：现有治疗方法和未来前景。
Expert Rev Proteomics. 2019 Oct;16(10):857-870. doi: 10.1080/14789450.2019.1676735. Epub 2019 Oct 17.
9
Apoptosis signal-regulating kinase 1/p38 signaling pathway negatively regulates physiological hypertrophy.凋亡信号调节激酶1/p38信号通路对生理性肥大起负向调节作用。
Circulation. 2008 Jan 29;117(4):545-52. doi: 10.1161/CIRCULATIONAHA.107.710434. Epub 2008 Jan 14.
10
Apoptosis signal-regulating kinase 1 inhibition attenuates human airway smooth muscle growth and migration in chronic obstructive pulmonary disease.凋亡信号调节激酶 1 抑制可减轻慢性阻塞性肺疾病患者的气道平滑肌生长和迁移。
Clin Sci (Lond). 2018 Jul 31;132(14):1615-1627. doi: 10.1042/CS20180398.
引用本文的文献
1
Rational design and discovery of potent PROTAC degraders of ASK1: a targeted therapy in MASH.ASK1强效PROTAC降解剂的合理设计与发现：非酒精性脂肪性肝炎的靶向治疗
RSC Med Chem. 2025 Jun 6. doi: 10.1039/d5md00252d.
2
Discovery of Novel Pyridin-2-yl Urea Inhibitors Targeting ASK1 Kinase and Its Binding Mode by Absolute Protein-Ligand Binding Free Energy Calculations.通过绝对蛋白质-配体结合自由能计算发现靶向ASK1激酶的新型吡啶-2-基脲抑制剂及其结合模式。
Int J Mol Sci. 2025 Feb 12;26(4):1527. doi: 10.3390/ijms26041527.
3
Synthesis and biological evaluation of quinoxaline derivatives as ASK1 inhibitors.喹喔啉衍生物的合成及作为 ASK1 抑制剂的生物评价。
J Enzyme Inhib Med Chem. 2024 Dec;39(1):2414382. doi: 10.1080/14756366.2024.2414382. Epub 2024 Oct 21.
4
Discovery of benzoheterocyclic-substituted amide derivatives as apoptosis signal-regulating kinase 1 (ASK1) inhibitors.发现苯并杂环取代的酰胺衍生物作为凋亡信号调节激酶1（ASK1）抑制剂。
RSC Med Chem. 2024 Jan 30;15(3):856-873. doi: 10.1039/d3md00663h. eCollection 2024 Mar 20.
5
Discovery of dual rho-associated protein kinase 1 (ROCK1)/apoptosis signal-regulating kinase 1 (ASK1) inhibitors as a novel approach for non-alcoholic steatohepatitis (NASH) treatment.发现双rho相关蛋白激酶1（ROCK1）/凋亡信号调节激酶1（ASK1）抑制剂作为非酒精性脂肪性肝炎（NASH）治疗的新方法。
BMC Chem. 2024 Jan 3;18(1):2. doi: 10.1186/s13065-023-01081-3.
6
TGFβ1-driven SMAD2/3 phosphorylation and myofibroblast emergence are fully dependent on the TGFβ1 pre-activation of MAPKs and controlled by maternal leucine zipper kinase.TGFβ1 驱动的 SMAD2/3 磷酸化和肌成纤维细胞的出现完全依赖于 TGFβ1 对 MAPKs 的预先激活，并受母系亮氨酸拉链激酶控制。
Cell Signal. 2024 Jan;113:110963. doi: 10.1016/j.cellsig.2023.110963. Epub 2023 Nov 4.
7
Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病中心血管疾病风险的综合综述
J Cardiovasc Dev Dis. 2022 Nov 26;9(12):419. doi: 10.3390/jcdd9120419.
8
Anti-neuroinflammatory Effects and Brain Pharmacokinetic Properties of Selonsertib, an Apoptosis signal-regulating Kinase 1 Inhibitor, in mice.Selonsertib，一种凋亡信号调节激酶 1 抑制剂，在小鼠体内的抗神经炎症作用及脑内药代动力学特性。
Neurochem Res. 2022 Dec;47(12):3829-3837. doi: 10.1007/s11064-022-03777-9. Epub 2022 Oct 30.
9
Investigating the Mechanism of Inhibition of Cyclin-Dependent Kinase 6 Inhibitory Potential by Selonsertib: Newer Insights Into Drug Repurposing.探究塞洛西布抑制细胞周期蛋白依赖性激酶6抑制潜能的机制：药物重新利用的新见解
Front Oncol. 2022 May 26;12:865454. doi: 10.3389/fonc.2022.865454. eCollection 2022.
10
Recent Advances in Pain Management: Relevant Protein Kinases and Their Inhibitors.疼痛管理的最新进展：相关蛋白激酶及其抑制剂
Molecules. 2021 May 4;26(9):2696. doi: 10.3390/molecules26092696.
本文引用的文献
1
Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease.ASK1抑制剂GS-4997用于糖尿病肾病患者的2期临床试验设计
Nephron. 2015;129(1):29-33. doi: 10.1159/000369152. Epub 2014 Dec 17.
2
ASK1 pharmacophore model derived from diverse classes of inhibitors.源自不同类型抑制剂的ASK1药效团模型。
Bioorg Med Chem Lett. 2014 Sep 15;24(18):4418-4423. doi: 10.1016/j.bmcl.2014.08.011. Epub 2014 Aug 12.
3
Crystal structures of ASK1-inhibtor complexes provide a platform for structure-based drug design.ASK1 抑制剂复合物的晶体结构为基于结构的药物设计提供了一个平台。
Protein Sci. 2013 Aug;22(8):1071-7. doi: 10.1002/pro.2298. Epub 2013 Jul 3.
4
Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors.设计并评价咪唑并[1,2-a]吡啶类化合物作为新型强效 ASK1 抑制剂。
Bioorg Med Chem Lett. 2012 Dec 15;22(24):7326-9. doi: 10.1016/j.bmcl.2012.10.084. Epub 2012 Oct 23.
5
Activation mechanisms of ASK1 in response to various stresses and its significance in intracellular signaling.ASK1响应各种应激的激活机制及其在细胞内信号传导中的意义。
Adv Biol Regul. 2013 Jan;53(1):135-44. doi: 10.1016/j.jbior.2012.09.006. Epub 2012 Sep 13.
6
Intracellular shuttling and mitochondrial function of thioredoxin-interacting protein.硫氧还蛋白相互作用蛋白的细胞内穿梭和线粒体功能。
J Biol Chem. 2010 Feb 5;285(6):3997-4005. doi: 10.1074/jbc.M109.034421. Epub 2009 Dec 3.
7
The roles of ASK family proteins in stress responses and diseases.ASK 家族蛋白在应激反应和疾病中的作用。
Cell Commun Signal. 2009 Apr 24;7:9. doi: 10.1186/1478-811X-7-9.
8
Group efficiency: a guideline for hits-to-leads chemistry.基团效率：从活性分子到先导化合物的化学研究指南。
ChemMedChem. 2008 Aug;3(8):1179-80. doi: 10.1002/cmdc.200800132.
9
The influence of drug-like concepts on decision-making in medicinal chemistry.类药概念对药物化学决策的影响。
Nat Rev Drug Discov. 2007 Nov;6(11):881-90. doi: 10.1038/nrd2445.
10
Ligand efficiency: a useful metric for lead selection.配体效率：先导化合物筛选的有用指标。
Drug Discov Today. 2004 May 15;9(10):430-1. doi: 10.1016/S1359-6446(04)03069-7.
Zotero 插件